[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

2019 BEP Versus BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Relapsed Lymphoma. A Single Center Retrospective Review of Two Contemporaneous Cohorts

Program: Oral and Poster Abstracts
Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster I
Saturday, December 10, 2011, 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center)

Paolo F. Caimi, MD1, Ashley Rosko, MD1*, Pingfu Fu, Ph., D.2*, Huda S. Salman, MD1*, Tamila L. Kindwall-Keller, DO3, Brenda W. Cooper, MD1* and Hillard M. Lazarus, MD FACP4

1Medicine - Hematology and Oncology, University Hospitals Case Medical Center, Cleveland, OH
2Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH
3Department of Internal Medicine, University of Virginia Medical Center, Charlottesville, VA
4Medicine, University Hospitals Case Medical Center, Cleveland, OH

High-dose chemotherapy (HDC) followed by autologous hematopoietic cell transplantation (AHCT) has been shown to result in better outcomes than conventional salvage chemotherapy for treatment of relapsed Hodgkin (Lancet 2002;359:2065-71) and non – Hodgkin lymphoma patients (N Engl J Med 1995;333:1540-5).

The relative efficacy of different conditioning regimens is still uncertain. Our center has had extensive experience with BEP, consisting of BCNU (600mg/m2), etoposide (2400mg/m2) and cisplatin (200mg/m2) (Lazarus HM, J Clin Oncol 1992;10:1682-9) with more than 150 patients transplanted using this conditioning regimen. We have observed it to be efficacious and associated with a low incidence of transplant-related mortality (Biol Blood Marrow Transplant 2005;11:13-22). The purpose of this analysis is to compare the outcomes of patients transplanted with BEP with a contemporaneous cohort of patients transplanted with BEAM (BCNU 300mg/m2, etoposide 800mg/m2, cytarabine 1600mg/m2, melphalan 140 mg/m2).

 We performed a retrospective analysis of 55 consecutive relapsed lymphoma patients who had either BEAM or BEP preparative therapy for AHCT between 2005 and 2010 at our institution. Given the potential for nephrotoxicity and ototoxicity of cisplatin, patients were selected to receive BEAM if they had previous renal dysfunction (any elevation of serum creatinine) or had previous hearing loss. All patients received corticosteroids for prophylaxis of BCNU – induced pneumonitis.

The Mann – Whitney test was used for analysis of continuous variables, Fisher's exact test for categorical data, while survival analysis was performed with the Kaplan – Meier method.

Twenty-four patients received BEAM and 31 received BEP. The median age was higher in BEAM-treated patients (51 vs. 43 years, p = 0.0392). Other baseline characteristics were comparable between both cohorts: gender (male 54 vs. 58%, p = 0.791); diagnosis (NHL 75 vs. 77.4%, p = 1.000); status of disease at transplant (partial remission or worse 33.3 vs. 35.5%, p = 1.000); median number of previous therapies (2 in both groups, p = 0.51).  The rate of non-renal comorbidities was higher in the BEAM cohort, but the difference was not statistically significant (45.8 vs. 32.3%, p = 0.403). The median CD34 cell dose was similar in both groups (6.252 x106 vs. 6.475  x106 CD34 cells/µL, p = 0.842).

The rate of complications, including bacteremia, other infections, mucositis, diarrhea and renal dysfunction were not statistically different (Table 1). The small sample size may have prevented us from observing a statistical difference in cardiac toxicity.

Table 1. Complications observed after BEAM or BEP conditioning for Autologous Hematopoietic Cell Transplantation

BEAM (%)

BEP (%)

Bacteremia

45.8

35.5

p = 0.580

Non – bacteremic infections

37.5

41.9

p = 0.787

Mucositis

54.2

58.1

p = 0.791

Diarrhea

79.1

64.5

p = 0.370

Increase in serum creatinine > 50%

12.5

16.1

p = 1.000

Cardiac complications

16.7

3.2

p = 0.153

BCNU pneumonitis

4.2

6.4

p = 1.000

The median follow up time for the whole cohort was 31 months (28 vs. 34 months, p 0.267). Relapse free survival (RFS) after 36 months was 81.1% and 82.9% for BEAM and BEP, respectively (p = 0.693) (Figure 1). Overall survival at 24 months was 89.6% for BEAM and 90.8% for BEP (p = 0.371) (Figure 2). Among patients transplanted in partial response or worse, the median RFS was 57 months after BEAM and 66 months after BEP (p = 0.3173). There were no deaths in the first 100 days after transplant for both cohorts.  There were no differences in the median number of days from hematopoietic cell infusion to discharge (12.5 vs. 12.0 days, p = 0.600) or achievement of ANC >500/µL (10 days for both cohorts, p = 0.415).

In conclusion, BEP conditioning achieved comparable engraftment, toxicity and survival outcomes to those achieved by BEAM for treatment of relapsed lymphoma patients. BEP is therefore a valid alternative for treatment of this patient population. The BCNU dose in BEP is twice that in BEAM, but we continue to observe limited rates of BCNU – induced pneumonitis. BEP may be preferable over BEAM in patients with underlying cardiac comorbidity. Longer follow up and prospective trials will help in identifying variables that aid in the selection of patients for the most appropriate conditioning regimen.

Description: RFS Description: Overall Survival

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH